Primary study · included by 1 review
Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
Iakovou 2015 · Iakovou Ioannis, Goulis Dimitrios G, Tsinaslanidou Zinovia, et al. · Head & neck · 2016
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · within 2 months after RIT | Prevalence 0.60 [0.28, 0.85] | 3 studies · 1502 participants | GRADE not reported |
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · more than 1 year after RIT | Prevalence 0.17 [0.10, 0.28] | 6 studies · 1005 participants | GRADE not reported |
Sialadenitis (pooled prevalence) Radioiodine (I131) therapy · between 6 months and 1 year after RIT | Prevalence 0.20 [0.12, 0.31] | 3 studies · 527 participants | GRADE not reported |
Sialadenitis (pooled prevalence) Radioiodine (I131) therapy · within 2 months after RIT | Prevalence 0.30 [0.12, 0.59] | 3 studies · 1563 participants | GRADE not reported |
Xerostomia (pooled prevalence) Radioiodine (I131) therapy · between 6 months and 1 year after RIT | Prevalence 0.19 [0.14, 0.25] | 5 studies · 885 participants | GRADE not reported |
1 including review in total.